Compare SHAK & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | AUPH |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2014 | 2014 |
| Metric | SHAK | AUPH |
|---|---|---|
| Price | $71.13 | $15.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 4 |
| Target Price | ★ $117.29 | $17.25 |
| AVG Volume (30 Days) | ★ 2.2M | 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 354.17 | ★ 5075.00 |
| EPS | 0.37 | ★ 0.53 |
| Revenue | ★ $1,445,306,000.00 | $283,055,000.00 |
| Revenue This Year | $16.58 | $17.54 |
| Revenue Next Year | $15.07 | $15.74 |
| P/E Ratio | $190.05 | ★ $30.43 |
| Revenue Growth | 15.38 | ★ 20.38 |
| 52 Week Low | $51.60 | $10.34 |
| 52 Week High | $110.67 | $19.25 |
| Indicator | SHAK | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 56.82 |
| Support Level | $52.90 | $15.43 |
| Resistance Level | $97.35 | $16.33 |
| Average True Range (ATR) | 2.90 | 0.51 |
| MACD | 1.48 | 0.05 |
| Stochastic Oscillator | 79.32 | 88.93 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.